These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 30003596)

  • 1. Identification and tracking of Addictovigilance signals in general practice: which interactions between the general practitioners and the French Addictovigilance Network?
    Gentile G; Jego M; Spadari M; Griffiths K; Jouanjus E; Micallef J
    Fundam Clin Pharmacol; 2018 Dec; 32(6):643-651. PubMed ID: 30003596
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Twenty-five years of the French Addictovigilance Network (FAN)].
    Micallef J; Mallaret M
    Therapie; 2016 Sep; 71(4):375-8. PubMed ID: 27296806
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Safety signal detection by the French Addictovigilance Network: Innovative methods of investigation, examples and usefulness for public health].
    Micallef J; Jouanjus É; Mallaret M; Lapeyre Mestre M
    Therapie; 2019 Dec; 74(6):579-590. PubMed ID: 31694770
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Signal identification in addictovigilance: the functioning of the French system.
    Jouanjus E; Gibaja V; Kahn JP; Haramburu F; Daveluy A
    Therapie; 2015; 70(2):113-31. PubMed ID: 25858567
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Identification of abuse/dependence cases by the French addictovigilance network (FAN): A pilot study of the addictovigilance center and the psychotherapeutic center of Nancy (France)].
    Barberot P; Gibaja V; Benkhedda C; Dobre D; Tournebize J; Kahn JP
    Therapie; 2019 Jun; 74(3):389-397. PubMed ID: 30392700
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Identification and tracking of addictovigilance signals in general practice: which interactions between the general practitioners and the French addictovigilance network?
    Lapeyre-Mestre M
    Fundam Clin Pharmacol; 2018 Dec; 32(6):641-642. PubMed ID: 30417491
    [No Abstract]   [Full Text] [Related]  

  • 7. Interest of large electronic health care databases in addictovigilance: Lessons from 15 years of pharmacoepidemiological contribution.
    Dupui M; Micallef J; Lapeyre-Mestre M
    Therapie; 2019 Apr; 74(2):307-314. PubMed ID: 30798951
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Addictovigilance contribution during COVID-19 epidemic and lockdown in France.
    Lapeyre-Mestre M; Boucher A; Daveluy A; Gibaja V; Jouanjus E; Mallaret M; Peyrière H; Micallef J;
    Therapie; 2020; 75(4):343-354. PubMed ID: 32660776
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [From psychoactive medicines to addictovigilance in French Public Health Code (1990-2017)].
    Baumevieille M; Perri-Plandé J; Miremont-Salamé G; Daveluy A; Haramburu F
    Therapie; 2019 Jun; 74(3):375-382. PubMed ID: 30193805
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Involvement of addictovigilance in emergency department for the detection of abuse and dependence cases: 3 years of experience].
    Serre A; Eiden C; Gourhant V; Laureau M; Perier D; Giraud I; Sebbane M; Peyrière H
    Therapie; 2018 Dec; 73(6):501-509. PubMed ID: 30017376
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Addictovigilance in women, the hidden part of the iceberg?
    Lapeyre-Mestre M
    Therapie; 2023; 78(2):157-164. PubMed ID: 36280399
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The management of opiate use disorders in France: results of an observational survey of general practitioners.
    Poloméni P; Bronner C; Fry F; Ravoninjatovo B; Fatseas M
    Addict Sci Clin Pract; 2015 Jun; 10():16. PubMed ID: 26117831
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Use of new psychoactive substances to mimic prescription drugs: The trend in France.
    Batisse A; Eiden C; Peyriere H; Djezzar S;
    Neurotoxicology; 2020 Jul; 79():20-24. PubMed ID: 32240674
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Gabapentinoid Abuse in France: Evidence on Health Consequences and New Points of Vigilance.
    Tambon M; Ponté C; Jouanjus E; Fouilhé N; Micallef J; Lapeyre-Mestre M;
    Front Psychiatry; 2021; 12():639780. PubMed ID: 33613345
    [No Abstract]   [Full Text] [Related]  

  • 15. Medical complications of psychoactive substances with abuse risks: Detection and assessment by the network of French addictovigilance centres.
    Peyrière H; Eiden C; Mallaret M; Victorri-Vigneau C
    Therapie; 2016 Dec; 71(6):563-573. PubMed ID: 27499243
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Chemsex practice in France: An update in Addictovigilance data.
    Batisse A; Eiden C; Deheul S; Monzon E; Djezzar S; Peyrière H
    Fundam Clin Pharmacol; 2022 Apr; 36(2):397-404. PubMed ID: 34494320
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Drug abuse monitoring: which pharmacoepidemiological resources at the European level?
    Lapeyre-Mestre M; Dupui M
    Therapie; 2015; 70(2):147-65. PubMed ID: 25858571
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ephenidine, diphenidine, and methoxphenidine complications reported to the French Addictovigilance Network.
    Eiden C; Leone-Burgos S; Serre A; Carton L; Gerardin M; Le Boisselier R; Gibaja V; Monzon E; Fouilhe N; Boucher A; Peyriere H;
    Fundam Clin Pharmacol; 2018 Dec; 32(6):654-662. PubMed ID: 29956843
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Surveillance system on drug abuse: Interest of the French national OPPIDUM program of French addictovigilance network].
    Frauger E; Pochard L; Boucherie Q; Giocanti A; Chevallier C; Daveluy A; Gibaja V; Caous AS; Eiden C; Authier N; Le Boisselier R; Guerlais M; Jouanjus É; Lepelley M; Pizzoglio V; Pain S; Richard N; Micallef J;
    Therapie; 2017 Sep; 72(4):491-501. PubMed ID: 28343650
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Health consequences of cocaine use in France: data from the French Addictovigilance Network.
    Eiden C; Vincent M; Serrand C; Serre A; Richard N; Picot MC; Frauger E; Fouilhé N; Daveluy A; Peyrière H;
    Fundam Clin Pharmacol; 2021 Apr; 35(2):455-465. PubMed ID: 32854152
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.